CytoCore Announces Multi Year Distribution Agreement for Exclusive Distribution of...

CytoCore Announces Multi Year Distribution Agreement for Exclusive Distribution of QuantRx's PadKit(R) for Cytology and HPV

CHICAGO--(Business Wire)--
CytoCore Inc. (OTCBB:CYOE), the developer of cost-effective,
highly accurate screening systems for early detection of gynecological
cancers and sexually transmitted diseases announced an exclusive
agreement with QuantRx Biomedical Corporation (OTCBB:QTXB) to
distribute its PadKit(R) Collection Kit to provide samples for
Cytology and Human Papilloma Virus (HPV) diagnostics, for the
worldwide women's health laboratory market.

Richard Domanik, President and Chief Operating Officer of CytoCore
stated, "We are excited to be able to expand our support of the
worldwide women's health market with this truly innovative product.
QuantRx has done a remarkable job in perfecting the pad technology,
and we are pleased to move into the next phase of product marketing
through our partnership. QuantRx will be our exclusive manufacturer
for this product, which allows us to introduce a new paradigm in
cytology sample collection for gynecological cytology. PadKit(R),
which complements the capabilities of our SoftPap(R) Collector,
provides us with a convenient and largely technique independent means
for collecting a gynecological sample for both conventional and
AIPS-based cytological, HPV and other tests."

"CytoCore is focused on the Cytology market, and brings decades of
expertise to this market. This agreement will allow QuantRx to
accelerate its PAD technology to the market and focus our in-house R&D
efforts on new applications," said William Fleming, QuantRx's Chief
Science Officer. "The completion of this project revalidates QuantRx's
strategic position in the diagnostic market as a developer and
manufacturer of new products and cutting edge technology."

CytoCore, Inc.

CytoCore develops cost-effective, highly accurate screening
systems for early detection of gynecological cancers and sexually
transmitted diseases. Designed for easy deployment at a laboratory or
at the point-of-care, the CytoCore suite of sample collection
technologies assists in the detection of cervical, endometrial, and
other cancers, as well as the Human Papilloma Virus. The CytoCore
Solutions(TM) System is being developed to provide medical
practitioners with highly accurate, low-cost, cervical and uterine
cancer screening systems that can be seamlessly integrated into
existing medical models. More information is available at:
www.CytoCoreInc.com.

About QuantRx Biomedical (www.quantrx.com)

QuantRx Biomedical Corporation (OTCBB:QTXB) is a broad-based
diagnostics company focused on the development and commercialization
of innovative diagnostic products based on its patented technology
platforms for the worldwide healthcare industry. With synergistic
expertise in the discovery of diagnostic platforms and the
commercialization of products for use by healthcare professionals and
consumers, QuantRx is focused on providing more accurate, reliable,
and faster diagnoses that result in improved patient care.

Certain statements in this release are forward-looking. These
statements are based on CytoCore's current expectations and involve
many risks and uncertainties, such as the company's inability to
obtain sufficient financing, the possibility that clinical trials will
not substantiate CytoCore's expectations with respect to the CytoCore
Solutions(TM) System, and other factors set forth in reports and
documents filed by CytoCore with the Securities and Exchange
Commission. Actual results may differ materially from CytoCore's
current expectation depending upon a number of factors affecting the
Company's business. These factors include, among others, risks and
uncertainties detailed in the Company's periodic public filings with
the Securities and Exchange Commission, including but not limited to
the Company's Annual Report on Form 10-KSB for the year ended December
31, 2007. Except as expressly required by law, CytoCore undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.

CytoCore, Inc.
Robert McCullough, Jr., 312-222-9550
or
EVC Group
Douglas Sherk or Matthew Selinger, 415-896-6820
mselinger@evcgroup.com

Copyright Business Wire 2008